Skip to main content
. 2020 Apr 14;11:1833. doi: 10.1038/s41467-020-15290-0

Fig. 3. Oral administration of NHWD-870 strongly suppressed the growth of established lung tumor, ovarian tumor, lymphoma, and melanoma in vivo.

Fig. 3

a Tumor growth curves for H526 SCLC tumor-bearing mice (n = 6) treated with the indicated compounds for 21 days. PO, oral administration; QD, once daily; BID, twice daily. b–d Tumor growth curves for A2780 ovarian tumor (n = 5) (b), TMD8 large B cell lymphoma (n = 6) (c), and B16F10 melanoma (n = 5) (d) bearing mice treated with the indicated compounds once daily for 11-21 days. e, f Tumor growth curves for A375 melanoma (n = 6) (e), and patient-derived xenograft (PDX) of melanoma (n = 5) (f) bearing mice treated with the indicated compounds once daily (5 days on, 2 days off) for 21 days. For d–f, NHWD-870 used is NHWD-870-HCl synthesized using Suzuki coupling route. Data are presented as mean ± SEM in (a, b, d, f) and mean + SEM in (c, e). p values were calculated using two-tailed, unpaired t tests. *p < 0.05; **p < 0.01; ***p < 0.001. Source data are provided as a Source Data file.